MCID: PRG002
MIFTS: 32

Progesterone-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Positive Breast Cancer

MalaCards integrated aliases for Progesterone-Receptor Positive Breast Cancer:

Name: Progesterone-Receptor Positive Breast Cancer 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060077

Summaries for Progesterone-Receptor Positive Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the presence of progesterone receptors.

MalaCards based summary : Progesterone-Receptor Positive Breast Cancer is related to breast sarcoma and endometrial cancer. An important gene associated with Progesterone-Receptor Positive Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Progesterone and Toremifene have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and endothelial.

Related Diseases for Progesterone-Receptor Positive Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 breast sarcoma 30.6 PGR ERBB2
2 endometrial cancer 29.6 PGR ESR2 ESR1 ERBB2 CYP19A1
3 breast cancer 10.4
4 bartholin's gland adenoma 10.4 PGR ESR1
5 bartholin's gland adenoid cystic carcinoma 10.4 PGR ESR1
6 uterine corpus adenosarcoma 10.3 PGR ESR1
7 bartholin's gland benign neoplasm 10.3 PGR ESR1
8 chronic tympanitis 10.3 PGR ESR1
9 vestibular gland benign neoplasm 10.3 PGR ESR1
10 granulomatous endometritis 10.3 PGR ESR1
11 vulvar syringoma 10.3 PGR ESR1
12 lung leiomyoma 10.3 PGR ESR1
13 adult type testicular granulosa cell tumor 10.3 PGR ESR1
14 scirrhous adenocarcinoma 10.3 PGR ERBB2
15 cervical clear cell adenocarcinoma 10.3 PGR ESR1
16 lipid-rich breast carcinoma 10.3 PGR ERBB2
17 ovarian seromucinous carcinoma 10.3 PGR ESR1
18 subserous uterine fibroid 10.3 PGR CYP19A1
19 apocrine adenosis of breast 10.3 PGR ERBB2
20 breast squamous cell carcinoma 10.3 ESR1 ERBB2
21 liver leiomyoma 10.3 PGR ESR1
22 intravenous leiomyomatosis 10.3 PGR ESR1
23 intracranial meningioma 10.3 PGR ESR1
24 luminal breast carcinoma b 10.3 PGR ERBB2
25 diffuse peritoneal leiomyomatosis 10.3 PGR CYP19A1
26 breast mucinous carcinoma 10.3 PGR ERBB2
27 vulvar leiomyoma 10.3 PGR ESR1
28 bizarre leiomyoma 10.3 PGR ESR1
29 breast adenoma 10.3 PGR ESR1
30 nonmucinous bronchioloalveolar adenocarcinoma 10.3 ESR2 ESR1
31 gastric diffuse adenocarcinoma 10.3 PGR ERBB2
32 benign metastasizing leiomyoma 10.3 PGR CYP19A1
33 linitis plastica 10.3 PGR ERBB2
34 prostate stromal sarcoma 10.3 PGR ESR1
35 bile duct cystadenoma 10.3 ESR2 ESR1
36 postmenopausal atrophic vaginitis 10.3 ESR2 ESR1
37 mammographic density 10.3 ESR1 CYP19A1
38 vaginitis 10.3 ESR2 ESR1
39 urethral benign neoplasm 10.3 PGR ESR1
40 ovarian endometrioid stromal sarcoma 10.3 PGR CYP19A1
41 triple-receptor negative breast cancer 10.3 PGR ERBB2
42 cervical adenosarcoma 10.3 PGR ESR1
43 breast papillomatosis 10.2 PGR ERBB2
44 biphasic synovial sarcoma 10.2 PGR ESR1
45 glassy cell carcinoma of the cervix 10.2 PGR ESR1 ERBB2
46 breast intraductal papillomatosis 10.2 PGR ESR1 ERBB2
47 intraductal papilloma 10.2 PGR ESR1 ERBB2
48 nipple carcinoma 10.2 PGR ESR1 ERBB2
49 primary peritoneal carcinoma 10.2 PGR ERBB2
50 breast scirrhous carcinoma 10.2 PGR ESR1 ERBB2

Graphical network of the top 20 diseases related to Progesterone-Receptor Positive Breast Cancer:



Diseases related to Progesterone-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Positive Breast Cancer

Drugs & Therapeutics for Progesterone-Receptor Positive Breast Cancer

Drugs for Progesterone-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
2
Toremifene Approved, Investigational Phase 2, Phase 3 89778-26-7 3005573
3
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
4
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
5
Zoledronic Acid Approved Phase 3 118072-93-8 68740
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
7 Hormones Phase 2, Phase 3
8 Hormone Antagonists Phase 2, Phase 3
9 Estrogens Phase 2, Phase 3
10 Estrogen Receptor Antagonists Phase 2, Phase 3
11 Estrogen Antagonists Phase 2, Phase 3
12 Antineoplastic Agents, Hormonal Phase 2, Phase 3
13 Estrogen Receptor Modulators Phase 2, Phase 3
14 Vitamins Phase 3
15 Diphosphonates Phase 3
16 Calciferol Phase 3
17 Calcium, Dietary Phase 3
18
Calcium Nutraceutical Phase 3 7440-70-2 271
19
Copper Approved, Investigational Phase 2 7440-50-8 27099
20
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
21
Tetrathiomolybdate Investigational Phase 2 16330-92-0
22 Aromatase Inhibitors Phase 2
23 Angiogenesis Inhibitors Phase 2
24 Chelating Agents Phase 2
25 Copper Supplement Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients Unknown status NCT02132000 Phase 2, Phase 3 toremifene or tamoxifen
2 An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy Completed NCT00050011 Phase 3 Zoledronic Acid;Letrozole
3 A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer Terminated NCT00674557 Phase 2 SOD1 inhibitor ATN-224;exemestane

Search NIH Clinical Center for Progesterone-Receptor Positive Breast Cancer

Genetic Tests for Progesterone-Receptor Positive Breast Cancer

Anatomical Context for Progesterone-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Positive Breast Cancer:

40
Breast, Bone, Endothelial

Publications for Progesterone-Receptor Positive Breast Cancer

Articles related to Progesterone-Receptor Positive Breast Cancer:

(show top 50) (show all 77)
# Title Authors PMID Year
1
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. 61
33495599 2021
2
miR-205 in Breast Cancer: State of the Art. 61
33375067 2020
3
Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468. 61
32686546 2020
4
Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. 61
32878860 2020
5
Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines. 61
32690069 2020
6
Precautions for Patients Taking Aromatase Inhibitors. 61
33532117 2020
7
Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women. 61
30955184 2019
8
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. 61
29939838 2018
9
Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact? 61
29772460 2018
10
Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. 61
29189387 2018
11
Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients. 61
30214216 2018
12
Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint. 61
28831439 2017
13
Tamoxifen Induced Pancreatitis: An Unusual Complication of Commonly used Drug. 61
28969260 2017
14
Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer. 61
28396965 2017
15
Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. 61
28251385 2017
16
[Advances in the research of pharmacogenomics of tamoxifen]. 61
29924509 2016
17
Single-nucleotide polymorphisms in PSCA and the risk of breast cancer in a Chinese population. 61
27050280 2016
18
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. 61
26298334 2016
19
Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer. 61
26232103 2015
20
Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer. 61
26363528 2015
21
Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer. 61
25573962 2015
22
Application status of tamoxifen in endocrine therapy for early breast cancer. 61
26136961 2015
23
Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer. 61
25424702 2015
24
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. 61
25403582 2015
25
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. 61
26161666 2015
26
The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 61
25488523 2015
27
Breast cancer in the setting of fertility-sparing treatment for endometrial cancer. 61
26075999 2014
28
Phytoestrogens induce apoptosis through a mitochondria/caspase pathway in human breast cancer cells. 61
24299158 2014
29
Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. 61
25009196 2014
30
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. 61
24799465 2014
31
Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. 61
24807917 2014
32
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. 61
24562823 2014
33
Challenges in the delivery of quality breast cancer care: initiation of adjuvant hormone therapy at an urban safety net hospital. 61
24345397 2014
34
Tamoxifen-induced acute pancreatitis - a case report. 61
26327832 2014
35
Body size, modifying factors, and postmenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area Breast Cancer Study. 61
23762816 2013
36
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. 61
23788750 2013
37
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. 61
23996142 2013
38
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. 61
23579222 2013
39
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. 61
23971947 2013
40
Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. 61
23922822 2013
41
Development of patients' decision aid for older women with stage I breast cancer considering radiotherapy after lumpectomy. 61
22331002 2012
42
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. 61
22763464 2012
43
Progesterone and levonorgestrel regulate expression of 17βHSD-enzymes in progesterone receptor positive breast cancer cell line T47D. 61
22564730 2012
44
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. 61
22548922 2012
45
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. 61
22395643 2012
46
Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors. 61
21916581 2011
47
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy. 61
20622644 2011
48
Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area breast cancer study. 61
21084558 2011
49
CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic. 61
20877451 2010
50
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. 61
20705559 2010

Variations for Progesterone-Receptor Positive Breast Cancer

Expression for Progesterone-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Positive Breast Cancer.

Pathways for Progesterone-Receptor Positive Breast Cancer

GO Terms for Progesterone-Receptor Positive Breast Cancer

Biological processes related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.43 PGR ESR2 ESR1
2 steroid hormone mediated signaling pathway GO:0043401 9.16 PGR ESR1
3 intracellular estrogen receptor signaling pathway GO:0030520 8.96 ESR2 ESR1
4 intracellular steroid hormone receptor signaling pathway GO:0030518 8.8 PGR ESR2 ESR1

Molecular functions related to Progesterone-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear receptor activity GO:0004879 9.43 PGR ESR2 ESR1
2 steroid hydroxylase activity GO:0008395 9.4 CYP2D6 CYP19A1
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.37 CYP2D6 CYP19A1
4 estrogen receptor activity GO:0030284 9.32 ESR2 ESR1
5 estrogen response element binding GO:0034056 9.16 ESR2 ESR1
6 steroid binding GO:0005496 9.13 PGR ESR2 ESR1
7 steroid hormone receptor activity GO:0003707 8.8 PGR ESR2 ESR1

Sources for Progesterone-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....